About BioReliance
BioReliance is a Healthcare company based in Rockville (United States) founded in 1947, and was acquired by Sigma Aldrich in January 2012. Biosafety testing, biomanufacturing, and toxicology services are offered to clients. BioReliance offers products and services including Contract Testing, Viral Clearance Testing, Analytical Development, Blazar Platform, and Provise Clearance Service. Its focus areas include Life Sciences, Genomics, Genomics Services and Sequencing. Its competitors include Avidity Biosciences, Sutro Biopharma and Antheia; 3 of its 3 listed competitors have raised funding.
Company details
Founded in 1947 and based in Rockville, United States, BioReliance operates in the biotechnology sector. Testing and manufacturing services are provided, including cell line and virus bank characterization, raw material testing, analytical services for biologics, immuno-assays, cell-based assays, bulk and final product release testing, viral clearance studies, cleaning validation, biorespiratory and biodistribution services, next-generation sequencing, genetic toxicology, and manufacturing of cell banks, virus banks, gene therapies, and viral vaccines.
- Headquarters Rockville, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website bioreliance.com
- Social LinkedIn X
- Acquired by Sigma Aldrich (Jan 2012)
- Investors
- Acquired bySigma Aldrich
(Jan 2012)
Products & Services of BioReliance
BioReliance offers a comprehensive portfolio of products and services, including Contract Testing, Viral Clearance Testing, Analytical Development, Blazar Platform, and Provise Clearance Service.
Testing for biologics safety and purity in pharmaceutical development.
Studies to remove viruses from bioprocesses for regulatory compliance.
Assays for drug substance and product quality attributes analysis.
Technology for quick adventitious virus detection in biologics.
Expert-led viral clearance studies at dedicated facilities.
Investors in BioReliance
BioReliance has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Sigma Aldrich.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Biochemical and organic chemicals are developed for scientific research applications. | 1951 | sigmaaldrich.com | St. Louis, United States |
Investor details for BioReliance
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of BioReliance
3 dated milestones of BioReliance across 65 years, from founding to its latest funding, stage changes and deals.
- Founded BioReliance is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Sigma Aldrich.
Competitors of BioReliance
BioReliance has 3 listed competitors in our database, 3 of them funded. They include Avidity Biosciences, Sutro Biopharma and Antheia.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. |
Detailed competitors of BioReliance
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioReliance
The website of BioReliance (bioreliance.com) receives about 2.1K visits a month and ranks #7,984,772 among all websites worldwide, #7,212 in Biotechnology and Pharmaceuticals.
- Monthly visits2.1K
▼ 8.9% vs previous month
- Global rank#7,984,772
among all websites
- Category rank#7,212
Health · Biotechnology and Pharmaceuticals
- Bounce rate45%
- Pages per visit1.6
- Average visit3 min 03 sec
- DevicesDesktop 68% Β· Mobile 32%
Websites whose visitors overlap most with BioReliance. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| covance.com | 100% | 20.2K | #688,229 | View details | |
| biopharma.com | 83% | 1.7K | #9,262,866 | View details | |
| rd-biotech.com | 82% | 1.7K | #11,064,917 | View details | |
| syngeneintl.com | 82% | 94K | #525,515 | View details | |
| avidbio.com | 82% | 12.3K | #1,697,368 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 11 similar websites and full traffic analytics for BioReliance
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as BioReliance (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioreliance
Complete news archive for BioReliance
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioReliance
BioReliance was founded in 1947.
BioReliance is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Founded in 1947 and based in Rockville, United States, BioReliance operates in the biotechnology sector. Testing and manufacturing services are provided, including cell line and virus bank characterization, raw material testing, analytical services for biologics, immuno-assays, cell-based assays, bulk and final product release testing, viral clearance studies, cleaning validation, biorespiratory and biodistribution services, next-generation sequencing, genetic toxicology, and manufacturing of cell banks, virus banks, gene therapies, and viral vaccines.
BioReliance's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
BioReliance offers Contract Testing, Viral Clearance Testing, Analytical Development, Blazar Platform, and Provise Clearance Service.
BioReliance has 1 investor. Key investors include Sigma Aldrich.
Yes. BioReliance was acquired by Sigma Aldrich in January 2012.

